A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

This is an open label, prospective, multicenter, non-comparative study to assess the
safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this
study is to fulfill the regulatory requirements as part of the RMP (Risk Management Plan)
for Tabrecta® (Capmatinib), as requested by Korea Health Authority, MFDS (Ministry of
Food and Drug Safety). The study is a post approval surveillance so there will be no comparator arm/drug nor
blinding process.

Dose/regimen should follow locally approved label and it could be adjusted as per the
decision from treating physician during treatment period, under their routine clinical
practice. Treatment duration is deemed to the decision from treating physician under
their routine clinical practice, since this study is a post approval surveillance and to
look for safety profiles happening under real world practice. There will be no
intervention from Novartis regarding dose/regimen and treatment duration.

This study will be completed after data collection of the last subject during the follow
up period. The follow up period is recommended for up to 24 weeks after enrollment or up
to the time of discontinuation of study drug (in case of early discontinuation) as per
linical judgement of treating physician.